



International Conference for Apheresis 1996

In conjunction with the 16th Congress of
Japanese Society for Apheresis

April 7-10, 1996
Kyoto, Japan

Program



SECRETARIAT

c/o Congress Corporation

Sunbird Bldg.

1-12-9 Oyodo-naka, Kita-ku

Osaka 531, Japan

Phone: +81 (6) 454-4811 Facsimile: +81 (6) 454-4711

CONTENTS

Welcoming Message	1
Committees	2
Conference Information	4
Information for Authors	5
Floor Plan	6
Program At-a-Glance	8
Scientific Program	12
Social Program	36
Registration	37
General Information	38
Map	

WELCOMING MESSAGE

It is both an honor and our very great pleasure to welcome you to Kyoto for the International Conference for Apheresis 1996, which is being held in conjunction with the 16th Annual Meeting of the Japan Society for Apheresis, the sponsor of this conference. We would like to take this opportunity to express our gratitude to Dr. Yukihiro Nose, Dr. Noboru Inoue, and their colleagues for their considerable efforts in founding the International Society for Apheresis.

As you know, this gathering is the Society's inaugural scientific meeting, and we are sure you share our enthusiasm for achieving the promise of this event, which represents a milestone in the study of apheresis.

Many fields of medicine now recognize the value of apheresis in the treatment of severe refractory diseases. For this treatment to continue developing, however, it is imperative that we expand our knowledge of medicine, biology, biophysics, and engineering in order to refine our tools and techniques. We are confident that this meeting will establish a standard of excellence for this field while providing younger physicians and technical specialists with the support they need when confronted with technical problems and a choice of treatments for severe conditions. Moreover, coming as it does immediately after the meeting of the International Society of Blood Transfusion in Chiba, Japan, this meeting is both timely and convenient for those with interests in blood transfusion and apheresis.

Early April in Kyoto is a special time. The former capital - renowned for its 1200-year history, ancient temples, unique gardens, and cultural ambiance - is adorned in cherry blossoms at the height of bloom. And the people of Kyoto are eager as always to show you their celebrated hospitality.

We trust that you will find your visit here both academically and culturally rewarding, and we look forward to working with you as we define the future of apheresis together.



Akira Yamamoto

Akira Yamamoto, M.D.
President
International Conference
for Apheresis 1996



Masashi Kodama

Masashi Kodama, M.D.
Secretary-general
International Conference
for Apheresis 1996.



Noritoshi Shibuya

Noritoshi Shibuya, M.D.
Program Director
International Conference
for Apheresis 1996

COMMITTEES

Organizing Committee

President	Akira Yamamoto
Vice-president	Kazuhiko Ito
Secretary-general	Masashi Kodama
Program Director	Noritoshi Shibuya

Local Organizing Committee

Tomiya Abe	Tetsuzo Agishi
Noboru Inoue Kazuko (wife)	Nobuhiko Koga
Kenji Maeda	Mitsuru Suzuki
Tohru Tani	Hiroshi Tsuda

International Advisory Board

Vittorio Bonomini (Italy)	Hans J. Gurland (Germany)
Paul Ivanovich (USA)	Horst Klinkmann (Germany)
Paul S. Malchesky (USA)	Yukihiko Nose (USA)
Toshitsugu Oda (Japan)	Yuichi Shiokawa (Japan)
Cees Th. S. Sibinga (The Netherlands)	Rakesh Srivastava (India)
Klaus V. Toyka (Germany)	Tsau Shin Yen (Taiwan)

International Program Committee

Rolf Bambauer (Germany)	Helmut Borberg (Germany)
David R. Cornblath (USA)	Hans H. Euler (Germany)
Bruce R. Gordon (USA)	Richard A.C. Hughes (UK)
János Jákó (Hungary)	Liliane Laroche (France)
C. Martin Lockwood (UK)	Gert Matthes (Germany)
Peter McClelland (UK)	Sergei N. Pokrovsky (Russia)
Walter Samtleben (Germany)	Ghodrat A. Siami (USA)
Akinori Sueoka (USA)	Gilbert R. Thompson (UK)
David H. Van Thiel (USA)	David G. Woodfield (New Zealand)

Local Scientific Program Committee

Noritoshi Shibuya, Chairman	Tadao Akizawa
Tetsuzo Agishi	Hiroyuki Hirasawa
Hiroshi Hashimoto	Kazuhiko Ito
Katsumi Ito	Nobuhiko Koga
Akio Kawamura	Soichi Sakai
Kenji Maeda	Masaru Shimizu
Sadayoshi Sekiguchi	Zenya Yamazaki
Tohru Tani	
Shinji Yuasa	

Organized by:

Organizing Committee for the International Conference for Apheresis 1996
The Kidney Foundation Japan

Supported by:

The Ministry of Education, Science & Culture
International Society for Artificial Organs
Japan Society for the Promotion of Science
Japan Medical Association
Japan Atherosclerosis Society
Japan Industrial Society for Artificial Organs
Japan Society of Blood Transfusion
Japanese Society of Nephrology
Japanese Society of Neurology
Japanese Society for Dialysis Therapy
Japanese Society of Neurological Therapeutics
Japanese Society for Apheresis
Japanese Society for Artificial Organs
The Japan Society of Hematology

Sponsored by:

The Commemorative Association for the Japan World Exposition

Benefactors:

The Pharmaceutical Manufacturers Association of Tokyo
Osaka Pharmaceutical Manufacturers Association
Asahi Medical Co., Ltd.
Baxter Limited
Cobe Laboratories, K. K.
Haemonetics Japan
Hoechst Japan Ltd.
Japan Immunoresearch Laboratories Co., Ltd.
Kaneka Corporation
Kuraray Co., Ltd.
Kawasumi Corporation, Ltd.
Nikkiso Co., Ltd.
Nipro Co., Ltd.
Nissho Co., Ltd.
Otsuka Pharmaceutical Factory, Inc.
Terumo Corporation
Toray Co., Ltd.
Torii Pharmaceutical Co., Ltd.
Ube Medical Co., Ltd.
Warner-Lambert Parke-Davis

CONFERENCE INFORMATION

Date

April 7-10, 1996

Venue

Kyoto International Conference Hall (KICH)
Takaraga-ike, Sakyo-ku, Kyoto 606, Japan
Phone: +81 (75) 705-1250 Facsimile: +81 (75) 705-1251

Conference Secretariat

c/o Congress Corporation
Sunbird Bldg.
1-12-9 Oyodo-naka, Kita-ku
Osaka 531, Japan
Phone: +81 (6) 454-4811 Facsimile: +81 (6) 454-4711

Official Language

The official language of the scientific program is English. No simultaneous translation will be provided.

Certificate of Attendance and Presentation

Certificates of attendance and presentation will be available on request after April 8, 1996, and must be collected by April 10, 1996; certificates will not be issued after the conference. Please submit your request at the Registration Desk well in advance and allow at least one full day for preparation of the certificate.

Identification Badges

Colored name badges will be provided during the conference. Please wear your badge for identification purposes and to ensure admission to the various functions.

Blue	Active member
Green	Residents, Students and Co-medical
Yellow	Exhibitor
Purple	Accompanying persons
Pink	Secretariat and other staff

Exhibition

An extensive exhibition will be held during the conference. It will feature surgical and medical equipment, and pharmaceutical products.

INFORMATION FOR AUTHORS

• Plenary Lecturs

- Time allotted for presentation 35 minutes
Audiovisual equipment Two 35-mm slide projectors

• Symposia and Workshops

- Time allotted for presentation To be determined by chairpersons
Audiovisual equipment One 35-mm slide projector

• Oral Sessions

- Time allotted for presentation 7 minutes plus 3 minutes for discussion
Audiovisual equipment One 35-mm slide projector


Note:

- *Speakers must operate slide projectors by themselves on the podium.
- *Please submit your slides to the slide reception desk located in front of each session room at least 30 minutes before your presentation. Please complete your slide preview at the Slide Preview Room (Room K) well before you submit them to the slide reception desk. Your slides will be returned to you at the slide reception desk to which you submitted them. There is no slide reception desk in the Slide Preview Room.
- *The Secretariat will not accept slides the day before your presentation.

• Poster Sessions

- Mounting board size 180 cm × 180 cm
Mounting schedule April 8-10, 09:00-10:30
Removal schedule April 8-10, 17:30-18:30

Time allotted for presentation: 3 minutes, plus 2 minutes for discussion
The Secretariat will provide poster numbers only.



(Back panel color is light yellow.)

• Official Language


The official language of the scientific program is English. No simultaneous translation will be provided.

• Manuscripts for Proceedings

Authors must submit manuscripts for the proceedings to the registration desk by **April 10**. Manuscripts received after this deadline will not be printed.


FLOOR PLAN

1st Floor



FLOOR PLAN

2nd Floor



PROGRAM

Sunday, April 7

Room	9:00	12:00	13:00
A			16th Annual Meeting of JSFA 13:00-16:30
C2	Technical Symposium (JSFA) 9:00-16:00		
D		Counselors Meeting of JSFA 12:00-13:00	

Monday, April 8

Room	9:00	10:10	10:30	13:00	13:40
A	Plenary 1 (Hughes, RAC) 9:00-9:35 Plenary 2 (Nose, Y) 9:35-10:10		Symposium 1 "Immunoabsorption versus intravenous immunoglobulin for autoimmune diseases"		
B1			Symposium 2 "Plasmapheresis and/or transplant for fulminant hepatic failure"		
B2		Coffee Break 10:10 -10:30	Symposium 3 "A new indication and innovation of plasma therapy"	Lunch 13:00-13:40	Oral Session 1 13:40-14:30
C1					Oral Session 2 13:40-14:30
C2					Oral Session 3 13:40-14:40
D	Technical Symposium (JSFA) 9:00-17:00				
G					Poster Session 1~3 13:40-14:55
H					Poster Session 4~5 13:40-14:25

AT-A-GLANCE

16:00	16:30	17:00	17:30	19:00	20:30	Room
16th Annual Meeting of JSFA 13:00-16:30				Opening Ceremony & Special Lecture 17:30-19:00	Welcome Reception 19:00-20:30 (Swan Room)	A
Technical Symposium (JSFA) 9:00-16:00						C2
		Business Meeting of JSFA 16:30-17:00				D

15:00	17:30	19:30	Room
			A
Workshop 1 "Plasmapheresis in inflammatory demyelinating polyneuropathies"			B1
Workshop 2 "Plasmapheresis as a hepatic assist for acute liver failure"			B2
Workshop 3 "Plasmapheresis in critical care"			C1
Workshop 4 "Role of apheresis as a treatment of malignant diseases"			C2
Technical Symposium (JSFA) 9:00-17:00		Mixer 17:30-19:30	D
			G
			H

Tuesday, April 9

Room	9:00	10:10	10:30	13:00	13:40	14:00
A	Plenary 3 (Adamson, JW) 9:00-9:35 Plenary 4 (Khatri, BO) 9:35-10:10			Symposium 4 "Peripheral blood stem cell apheresis"	General Assembly 13:00-14:00	
B1				Symposium 5 "Apheresis in the treatment of sepsis and multi-organ failure"		
B2				Symposium 6 "Has plasmapheresis a role in the treatment of collagen diseases?"		
C1		Coffee Break 10:10-10:30		Lunch 13:00-13:40	Oral Session 4 13:40-14:30	
C2					Oral Session 5 13:40-14:30	
G					Poster Session 6-8 13:40-15:00	
H					Poster Session 9-11 13:40-15:00	

Wednesday, April 10

Room	9:00	10:10	10:30	13:00	13:40
A	Plenary 5 (Agishi, T) 9:00-9:35 Plenary 6 (Thompson, GR) 9:35-10:10			Symposium 7 "LDL and Lp(a) apheresis"	
B1				Symposium 8 "Plasmapheresis in autoimmune neurologic diseases"	
B2				Symposium 9 "Extracorporeal photochemotherapy update"	
C1		Coffee Break 10:10-10:30		Lunch 13:00-13:40	Oral Session 6 13:40-14:30
C2					Oral Session 7 13:40-14:20
G					Poster Session 12-13 13:40-14:30
H					Poster Session 14-16 13:40-14:55

AT-A-GLANCE

15:00	17:30	18:00	20:00	Room
				A
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 5 "Donor apheresis: Recent advances and future development" </div>				B1
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 6 "Extracorporeal therapy for amyloidosis" </div>				B2
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 7 "Plasmapheresis for autoimmune skin diseases" </div>				C1
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 8 "Apheresis for the treatment of inflammatory bowel diseases" </div>				C2
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Banquet 18:00-20:00 (Sakura Room) </div>				G
				H

15:00	17:30			Room
				A
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 9 "Development and evaluation of new apheresis techniques in the treatment of atherosclerosis and some related diseases" </div>				B1
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 10 "Therapeutic cytapheresis" </div>				B2
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 11 "Use of filtration technology for reducing the infectivity of blood components" </div>				C1
<div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Workshop 12 "New devices" </div>				C2
				G
				H

SCIENTIFIC PROGRAM

April 8 (Mon.)

Plenary Lectures

PL-1	Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome Hughes, R.A.C. (UK) <i>Chairperson: Shibuya, N. (Japan)</i>	09:00-09:35 Room A
PL-2	Plasmapheresis: Historical perspective and new trends Nose, Y. (USA) <i>Chairperson: Ivanovich, P. (USA)</i>	09:35-10:10 Room A

Symposia

S-1	Immunoabsorption versus intravenous immunoglobulin for autoimmune diseases <i>Chairpersons: Haupt, W.F. (Germany) & Lockwood, C.M. (UK) ^{Nydegger, U.E.}</i>	10:30-13:00 Room A
------------	--	-----------------------

S-1-1 **Is there a role for therapeutic immunoabsorption?**

~~Lockwood, C.M. (UK)~~ *Griffin, S.V.*

S-1-2 **Immunomodulatory treatment of autoimmune diseases**

Nydegger, U.E. (Switzerland)

S-1-3 **Intravenous immunoglobulin therapy of autoimmune diseases**

Kazatchkine, M.D. (France)

S-1-4 **Sequential treatment of acute Guillain-Barré syndrome**

Haupt, W.F. (Germany)

S-1-5 **Recombinant human autoantigens as an extracorporeal immunoabsorbent in therapeutic apheresis**

Griffin, S.V. (UK)

S-1-6 **Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation**

Robinson, J.A. (USA)

S-2	Plasmapheresis and/or transplant for fulminant hepatic failure <i>Chairpersons: Muto, Y. (Japan) & Chang T.M.S. (Canada)</i>	10:30-13:00 Room B1
------------	--	------------------------

S-2-1 **Living - related liver transplantation in fulminant hepatic failure**

Tanaka, K. (Japan)

April, 8 (Mon.)

April 8 (Mon.)

- S-2-2 **Clinical and experimental studies on apheresis and development of a bioartificial liver in fulminant hepatic failure**
Nagaki, M. (Japan)
- S-2-3 **Development of bioartificial liver**
Chang, T.M.S. (Canada)
- S-2-4 **Experience with bioartificial liver**
Demetriou, A.A. (USA)
- S-2-5 **Usefulness of plasma exchange with hemodiafiltration as a bridge use for liver transplantation**
Fujita, S. (Japan)

S-3	A new indication and innovation of plasma therapy <i>Chairpersons: Ito, K. (Japan) & Borberg, H. (Germany)</i>	10:30-13:00 Room B2
------------	--	------------------------

- S-3-1 **Synergetic evaluation of the efficacy of hemapheretic therapies: Restabilization of the disturbed microcirculation and its quantification by in vitro blood tests and complexity assessment**
~~Schmid-Schönbein, H. (Germany)~~ *Hector, J.*
- S-3-2 **Extracorporeal haemorheotherapy with selective plasma protein elimination**
Schuff-Werner, P. (Germany)
- S-3-3 **Improvement of visual acuity in patients suffering from age related macular degeneration after extracorporeal treatment procedures**
Brunner, R. (Germany)
- S-3-4 **Extracorporeal haemorheotherapy of refractory angina pectoris**
Tauchert, M. (Germany)
- S-3-5 **Plasmapheresis for prevention of recurrent FGS of kidney allograft in adult recipients**
Iguchi, Y. (Japan)
- S-3-6 **Plasmapheresis combined with somatostatin is the successful treatment of porphyrias**
Medenica, R.D. (USA)

April 8 (Mon.)

Oral Sessions

O-1	Role of plasmapheresis in autoimmune diseases (I) <i>Chairpersons : Akizawa, T. (Japan) & Schneider, M. K. (Germany)</i>	13:40-14:30 Room B2
------------	--	------------------------

- O-1-01 **Immunoabsorption and plasmapheresis for habitual premature delivery case with anti RNP and SS-A antibody**
Hara, S. (Japan)
- O-1-02 **Therapeutic plasmapheresis for the prevention of fetal arrhythmia associated with anti SS-A antibody and anti SS-B antibody**
Miyakata, S. (Japan)
- O-1-03 **Randomized open trial to elucidate the effect of immunoabsorption of anti-DNA antibodies in SLE patients**
Tokuda, M. (Japan)
- O-1-04 **Changes in adhesion molecules on leukocyte and platelet during plasmapheresis**
Kinugasa, E. (Japan)
- O-1-05 **Comparison of three antibody elimination techniques: Plasmapheresis, anti-immunoglobulin adsorption, and Protein A adsorption**
Zeuner, R.A. (Germany)

O-2	Peripheral blood stem cell transplantation <i>Chairpersons : Fujiyama, Y. (Japan) & Sniecinski, I. (USA)</i>	13:40-14:30 Room C1
------------	--	------------------------

- O-2-06 **Peripheral blood stem cell transplantation for the treatment of advanced testicular cancer**
Koga, S. (Japan)
- O-2-07 **Effectiveness of peripheral blood stem cells transplantation in a patients with oncohematological diseases**
~~Fregatova, L. (Russia)~~ *Cancel*
- O-2-08 **Comparison of four methods for collection peripheral stem cells in 24 patients**
~~Schooneman, F. (France)~~ *Cancel*
- O-2-09 **Comparison of peripheral blood stem cells (PBSCS) mobilized with granulocyte colony-stimulating factor (G-CSF) after high dose single-agent chemotherapy with PBSCS mobilized with G-CSF alone**
Kobayashi, N. (Japan)
- O-2-10 **Kinetics of CD34⁺ cells or colony forming-units for granulocyte/macrophage in children undergoing apheresis**
Abe, T. (Japan)

April, 8 (Mon.)

April 8 (Mon.)

O-3 Evaluation of apheresis procedures <i>Chairpersons : Maeda, K. (Japan) & Srivastava, R. (India)</i>	13:40-14:40 Room C2
--	------------------------

- O-3-11 **A 1995 year with manual apheresis procedures**
Dimitrijević, G.M. (Yugoslavia)
- O-3-12 **Surface treated catheters for blood access for apheresis methods**
Bambauer, R. (Germany)
- O-3-13 **Control of protein loss in paraproteinemic patients during plasmapheresis**
~~Kalinin, N.N. (Russia)~~ *Cancel*
- O-3-14 **Platelet storage lesion assessed by changes in cellular indices: Comparison of three types of apheresis products with buffy coat derived PC**
Seghatchian, M.J. (UK)
- O-3-15 **Application of plasmapheresis in clinical practice**
~~Kerimov, A.A. (Azerbaijan)~~ *Cancel*
- O-3-35 **Anti-HLA antibody removal before transplantation**
Hendry, B.M. (UK)

=====**Poster Sessions**=====

P-1 LDL apheresis (I) <i>Chairperson : Shinoda, T. (Japan)</i>	13:40-14:05 Room G
---	-----------------------

- P-1-01 **LDL apheresis in familial hypercholesterolemia: Expérience of four years in 3 patients**
Brignon, P. (France)
- P-1-02 **Assessment of efficacy of LDL-apheresis by recovery process of plasma lipoproteins in a patient with homozygous familial hypercholesterolemia**
Mikami, Y. (Japan)
- P-1-03 **Low-density lipoprotein apheresis treatment for hyperlipidemia in patients with peripheral arterial occlusive disease**
Tsuchida, H. (Japan)
- P-1-04 **Clinical evaluation and the appropriate treatment for DFPP in familial hypercholesterolemia**
Yamane, S. (USA)
- P-1-05 **Regression of coronary artery disease in familial hypercholesterolemia: LDL apheresis coronary atherosclerosis prospective study**
Mokuno, H. (Japan)

April, 8 (Mon.)

P-2	LDL apheresis (II) <i>Chairperson : Higuchi, K. (Japan)</i>	14:05-14:30 Room G
------------	---	-----------------------

- P-2-06 **LDL-apheresis to reduce extremely elevated lipoprotein (a) P levels**
Bambauer, R. (Germany)
- P-2-07 **H.E.L.P. apheresis for prevention of graft vessel disease after heart transplantation**
~~Meiser, B.M. (Germany)~~ *Bruecker, w*
- P-2-08 **Effects of LDL apheresis on the retardation of progression of overt diabetic nephropathy**
Nakao, T. (Japan)
- P-2-09 **LDL-apheresis for post CABG patients**
Hashiyada, H. (Japan)
- P-2-10 **LDL-apheresis for prevention of restenosis after coronary angioplasty**
Shinoda, T. (Japan)

P-3	LDL apheresis (III) <i>Chairperson : Sanaka, T. (Japan)</i>	14:30-14:55 Room G
------------	---	-----------------------

- P-3-11 **Removal of plasma fibrinogen by LDL apheresis**
Tasaki, H. (Japan)
- P-3-12 **Effectiveness of LDL-apheresis treatment for dialysis patients accompanied by arteriosclerosis obliterans**
Sato, M. (Japan)
- P-3-13 **Prevention of atherosclerosis: LDL-apheresis in comparison to lipid-lowering drugs**
Schiel, R. (Germany)
- P-3-14 **Generated bradykinin by LDL adsorption induces serum NO in patients with arteriosclerotic obliteration**
Ueki, Y. (Japan)
- P-3-15 **Therapeutic trial of Alzheimer disease using LDL-apheresis**
Ishigaki, Y. (Japan)

P-4	Stem cell apheresis <i>Chairperson : Takahashi, T.A. (Japan)</i>	13:40-14:05 Room H
------------	--	-----------------------

- P-4-16 **European multicenter evaluation of the cobe spectra LRS leukoreduction system**
Müller, N. (Germany)

April, 8 (Mon.)

- P-4-17 **Stem cell collection for allogeneic transplantation**
Valbonesi, M. (Italy)
- P-4-18 **Evaluation of granulocyte colony-stimulating factor administration on normal granulocytopheresis donors**
Osada, K. (Japan)
- P-4-19 **Evaluation of pre-storage leukocyte-reduced PC collected by plateletpheresis**
Ogawa, Y. (Japan)
- P-4-20 **Enhanced efficacy of platelet collections by modified peak detection monitoring program in multi-component systems**
Takenaka, M. (Japan)

P-5 Leukocytopheresis <i>Chairperson : Matsuoka, J. (Japan)</i>	14:05-14:25 Room H
---	-----------------------

- P-5-22 **Use of cell separators in cascade filtration in India: An economic solution**
Srivastava, R. (India)
- P-5-23 **A case report of resistant erythroderma treated by successful leukocytopheresis**
Shiraishi, T. (Japan)
- P-5-24 **Efficient collection of peripheral blood stem cells in chronic myelocytic leukemia patients accompanied with high volume of platelets**
~~Komatsu, F. (Japan)~~ *Cancel*
- P-5-25 **Therapeutic leukoapheresis with interferon in cancer patients**
Nita, H. (Japan)

==== Workshops =====

W-1 Plasmapheresis in inflammatory demyelinating polyneuropathies <i>Chairpersons: Koh, C.-S. (Japan) & Pineda, A.A. (USA)</i>	15:00-17:30 Room B1
--	------------------------

- W-1-1 **Plasmapheresis in inflammatory polyneuropathy**
Chiu, H.-C. (Taiwan)
- W-1-2 **Patterns of clinical response to plasma exchange**
Khatri, B.O. (USA)
- W-1-3 **Apheresis treatment of chronic demyelinating polyneuropathies and alternatives**
Pineda, A.A. (USA)

April 8 (Mon.)

W-1-4 **The role of immunoadsorption plasmapheresis in chronic inflammatory demyelinating polyneuropathy**
Koh, C.-S. (Japan)

W-1-5 **The use of plasmapheresis in patients with HIV neuropathies**
Hirose, T.G. (USA) & Kiprof, D.D. (USA)

W-2 Plasmapheresis as a hepatic assist for acute liver failure <i>Chairpersons: Hassanein, T.I. (USA) & Michalopoulos, G.K. (USA)</i>	15:00-17:30 Room B2
--	------------------------

W-2-1 **Conventional care of FHF: Medical and surgical aspects**
Hassanein, T.I. (USA)

W-2-2 **New therapeutic attempts in the treatment of fulminant hepatitis in Japan**
Yoshida, M. (Japan)

W-2-3 **Extracorporeal liver assist: Metabolic support for the failing liver**
~~Sussman, N.L. (USA)~~ *Cancel*

W-2-4 **Guides on future fulminant hepatic failure treatment based on cellular dynamics and HGF changes**
Michalopoulos, G.K. (USA)

W-2-5 **Possible role of enhanced cytokine production in the pathogenesis of postoperative acute liver failure**
Asanuma, Y. (Japan)

W-3 Plasmapheresis in critical care <i>Chairpersons: Hirasawa, H. (Japan) & Reeves, J.H. (Australia)</i>	15:00-17:30 Room C1
---	------------------------

W-3-1 **H.E.L.P. in septicemia: First clinical experiences**
Samtleben, W. (Germany)

W-3-2 **Plasmapheresis in multiple organ failure-The Japanese experience**
Hirasawa, H. (Japan)

W-3-3 **The use of continuous arteriovenous hemofiltration or plasma exchange during septic shock**
Natanson, C. (USA)

W-3-4 **Plasmapheresis in human sepsis: The case for its use**
Reeves, J.H. (Australia)

W-3-5 **Double filtration plasmapheresis for extracorporeal immunomodulation in treatment of rapidly progressive glomerulonephritis**
Srivastava, R. (India)

April 8 (Mon.)

- W-3-6 **Comparison of Apache III, II for prediction of mortality in a multiple organ failure patients treated by plasma exchange**
Lin, K.-J. (Taiwan)

W-4 Role of apheresis as a treatment of malignant diseases <i>Chairpersons: Toge, T. (Japan) & Bambauer, R. (Germany)</i>	15:00-17:30 Room C2
--	------------------------

- W-4-1 **Plasma perfusion in the treatment of metastatic colorectal carcinoma: A randomized study**
Dufour, P.R. & Faradji, A. (France)
- W-4-2 **Therapeutic apheresis in malignancy**
Nand, S. (USA)
- W-4-3 **Low molecular weight protein apheresis and regression of breast cancer**
Lentz, M.R. (USA)
- W-4-4 **Adoptive immunotherapy of cancer with lymphokine-activated killer cell transfer combined with plasmapheresis**
Yamaguchi, Y. (Japan)
- W-4-5 **Removal of immunosuppressive factors with protein-A column in gastroenterological cancer**
Sugiyama, Y. (Japan)
- W-4-6 **Peripheral blood stem cell transplantation in breast cancer**
Lin, D.-T. (Taiwan)

April 9 (Tue.)

Plenary Lectures

PL-3	Placental/umbilical cord blood banking: A progress report Adamson, J.W. (USA) <i>Chairperson: Takaku, F. (Japan)</i>	09:00-09:35 Room A
PL-4	Present and future of immunomodulating therapy for multiple sclerosis Khatri, B.O. (USA) <i>Chairperson: Tashiro, K. (Japan)</i>	09:35-10:10 Room A

Symposia

S-4	Peripheral blood stem cell apheresis <i>Chairpersons: Harada, M. (Japan) & Hester, J.P. (USA)</i>	10:30-13:00 Room A
------------	---	-----------------------

- S-4-1 **Present status of blood cell mobilization, collection and transplantation: An overview**
~~Hester, J.P. (USA)~~ *Cancel*
- S-4-2 **The current status of the use of cytokins in collection of peripheral stem cells**
Sniecinski, I. (USA)
- S-4-3 **Characterization of peripheral blood stem cells**
Sonoda, Y. (Japan)
- S-4-4 **Pediatric experience of blood stem cell collection**
Kawano, Y. (Japan)
- S-4-5 **Collection and transplantation of peripheral blood stem cells in adults**
Miyamoto, T. (Japan)
- S-4-6 **Enhancement of cell processing in allogenic peripheral blood stem cell transplantation**
Takahashi, T.A. (Japan)

S-5	Apheresis in the treatment of sepsis and multi-organ failure <i>Chairpersons: Kodama, M. (Japan) & McClelland, P. (UK)</i>	10:30-13:00 Room B1
------------	--	------------------------

- S-5-1 **Overview of extracorporeal treatment of sepsis & MOF**
Werdan, K. (Germany) & Pilz, G. (Germany)
- S-5-2 **A new extracorporeal endotoxin hemoperfusion system in a porcine et-shock-model**
Staubach, K.H. (Germany)

April, 9 (Tue.)

- S-5-3 **Endotoxin elimination therapy on severe sepsis with toraymyxin**
Tani, T. (Japan)
- S-5-4 **A newly developed multi-adsorbent system based on micro-and nanospheres for the treatment of multi-organ failure**
Falkenhagen, D. (Austria)
- S-5-5 **Targeting endotoxemia in septic shock**
Danner, R.L. (USA)
- S-5-6 **Rationale for use of plasma exchange in MOF**
McClelland, P. (UK)

S-6	Has plasmapheresis a role in the treatment of collagen diseases? <i>Chairpersons: Hashimoto, H. (Japan) & Euler, H.H. (Germany)</i>	10:30-13:00 Room B2
------------	---	------------------------

- S-6-1 **Ineffectiveness of plasmapheresis in SLE nephritis**
Lewis, E.J. (USA) *Schneider.*
- S-6-2 **Plasmapheresis and subsequent pulse cyclophosphamide in SLE: A chance for treatment-free remission in an incurable disease?**
~~Euler, H.H. (Germany)~~ *Cancel*
- S-6-3 **Differential effects of different immunoadsorption devices in collagen vascular disorders**
Schneider, M.K. (Germany)
- S-6-4 **Outcome of collagen vascular diseases by the treatment of plasmapheresis**
Hashimoto, H. (Japan)
- S-6-5 **The efficacy of plasma- or leukocytapheresis for articular and extraarticular manifestations of rheumatoid arthritis**
Ogawa, H. (Japan)
- S-6-6 **Cryofilter apheresis in the treatment of cryoprecipitate induced diseases**
Siami, G.A. (USA)

==== Oral Sessions ====

O-4	Role of plasmapheresis in autoimmune diseases (II) <i>Chairpersons : Suzuki, M. (Japan) & Lewis, E.J. (USA)</i>	13:40-14:30 Room C1
------------	---	------------------------

- O-4-16 **Plasmapheresis in treatment of lupus nephritis and crescentic glomerulonephritis**
Grčevska, L.P. (Macedonia)

April 9 (Tue.)

- O-4-17 **Ig-immunoabsorption in a patient with SLE: Chyleous ascites and cytopenia**
Gaubitz, M. (Germany)
- O-4-18 **Application of granulomonocytes apheresis by G-1 column to the patients with rheumatoid arthritis**
Ito, O. (Japan)
- O-4-19 **Characteristics of a new anti-rheumatic therapy, granulocytapheresis with G-1 column, in human and rat**
Yanagihara, Y. (Japan)
- O-4-20 **Randomized open trial to compare the effectiveness of cryofiltration and leukapheresis in methotrexate-resistant RA patients**
Inoh, M. (Japan)

O-5	A new indication and development of plasma therapy	13:40-14:30
------------	---	-------------

Chairpersons : Abe, T. (Japan) & Liu, J.D. (China)

Room C2

- O-5-21 **H.E.L.P. for the treatment of different atherosclerotic diseases**
Walzl, M. (Austria)
- O-5-22 **Haemorheological intervention by heparin-induced plasma protein precipitation in patients with acute occlusion of the central retinal artery or with ischemic neuropathy of the optical nerve**
Schuff-Werner, P. (Germany)
- O-5-23 **Thirteen cases of ankylosing spondylitis treated with double filtration plasmapheresis**
Liu, J.D. (China)
- O-5-24 **Plasma exchange is greatly useful for infants with an intractable febrile disease**
Takagi, N. (Japan)
- O-5-25 **Immunosorbent for IgG apheresis: Synthesis and characteristics**
Pokrovsky, S.N. (Russia)

Poster Sessions

P-6	New devices and indication (I)	13:40-14:05
------------	---------------------------------------	-------------

Chairperson : Matsubara, S. (Japan)

Room G

- P-6-26 **Influence of ozone on biochemical properties of erythrocytes preliminary studies**
Szklennik, J. (Poland)

- P-6-27 **Voice synthesis menu in plasmapheresis machine**
Srivastava, R. (India)
- P-6-28 **A case of late onset hepatic failure saved by plasmapheresis and bilirubin perfusion treatment**
Tanaka, A. (Japan)
- P-6-29 **Comparative study of polyethylene plasma separator sterilized by ethylene oxide and gamma ray**
Nagano, T. (Japan)
- P-6-30 **Assessment of endotoxin permeability during hemodialysis with high-flux membranes**
Yokota, T. (Japan)

P-7 New devices and indication (II) <i>Chairperson : Tsuda, H. (Japan)</i>	14:05-14:30 Room G
---	-----------------------

- P-7-31 **Therapeutic apheresis software development in India**
Srivastava, R. (India)
- P-7-32 **Bronchial fluid level of neuron specific enolase as a marker for plasmapheresis efficiency in atopic bronchial asthma**
~~Gayeovich, A.A. (Russia)~~ *Cancel*
- P-7-33 **Predeposit autologous blood transfusion in gastroenterological surgery for cancer patients**
Omokawa, S. (Japan)
- P-7-34 **Simple method for obtaining the therapeutical doses of fraction of young red cells (neocytes) from the one donor**
Asadov, Ch.D. (Azerbaijan)
- P-7-35 **Gram-positive and negative bacterial contamination in chronic hemodialysis patients: Plasma levels of endotoxin and toxic shock syndrome Toxin-1**
Kobayashi, T. (Japan)

P-8 Systemic lupus erythematosus <i>Chairperson : Suzuki, K. (Japan)</i>	14:30-15:00 Room G
---	-----------------------

- P-8-36 **Removal of anaphylatoxins from the plasma of systemic lupus erythematosus patients by adsorption using dextran sulfate cellulose columns**
Matsuki, Y. (Japan)
- P-8-37 **Effect of immunoadsorption therapy in systemic lupus erythematosus**
Funachi, M. (Japan)

April 9 (Tue.)

- P-8-38 **Immunoabsorption in patients with SLE: In vitro investigations**
Schmitz-Linneweber, B. (Germany)
- P-8-39 **Synchronous application of hemoperfusion with activated carbon and pulse-therapy by methylprednisolone and cyclophosphane in SLE patients with unfavourable prognosis**
Shaikov, A.V. (Russia)
- P-8-40 **Systemic lupus erythematosus treated by plasmapheresis and immunomodulatory therapy**
~~Medenica, R.D. (USA)~~ *Lazovic, G.*
- P-8-41 **Plasmapheresis in treatment of progressive systemic lupus erythematosus**
Schiel, R. (Germany)
- P-8-42 **Plasma exchange in lupus anticoagulant-associated bleeding**
~~Bracey, A.W. (USA)~~ *Cancel.*
- P-8-43 **Kinetics of immunoglobulins, circulating immune-complexes, and fractional protein-clearances during immunoabsorption onto Protein-A sepharose in systemic lupus erythematosus**
Braun, N. (Germany)

P-9 Autoimmune neurologic diseases <i>Chairperson : Kawanami, S. (Japan)</i>	13:40-14:05 Room H
---	-----------------------

- P-9-44 **Effect of lymphocytapheresis on polymyositis**
Yamamoto, T. (Japan)
- P-9-45 **Plasma exchange and azathioprine in multiple sclerosis: A randomized single-masked crossover study**
Szpirt, W.M. (Denmark)
- P-9-46 **Role of immunoabsorption with double filtration plasmapheresis in acute myasthenic crisis**
Srivastava, R. (India)
- P-9-47 **Clinical experiences of double filtration plasmapheresis in the treatment of myasthenia gravis**
Yeh, J.-H. (Taiwan)
- P-9-48 **Role of intensive plasmapheresis in complete recovery of acute Guillain-Barré syndrome resistant to intravenous IgG**
Srivastava, R. (India)

April, 9 (Tue.)

P-10 Guillain-Barré syndrome and related disorders <i>Chairperson : Matsuo, H. (Japan)</i>	14:05-14:30 Room H
---	-----------------------

- P-10-49 **A case of chronic progressive Guillain-Barré syndrome: 7 years of successful treatment with intermittent therapeutic plasma-exchange**
Kresse, S. (Germany)
- P-10-50 **Comparative study of the efficacy of plasma exchange, immunoadsorption plasmapheresis and corticosteroid administration in the treatment of Guillain-Barré syndrome**
Yamazaki, M. (Japan)
- P-10-51 **Immunoadsorption plasmapheresis in inflammatory demyelinating disease**
Inoue, A. (Japan)
- P-10-52 **Apheresis therapy in Guillain-Barré syndrome and Fisher's syndrome**
Yoh, K. (Japan)
- P-10-53 **Successful treatment with immuno-adsorption plasmapheresis therapy for Miller-Fisher syndrome**
Suenaga, M. (Japan)

P-11 Multiple organ failure <i>Chairperson : Imaizumi, H. (Japan)</i>	14:30-15:00 Room H
--	-----------------------

- P-11-54 **Clinical analysis of patients with multiple organ failure treated with plasmapheresis**
Uchida, K. (Japan)
- P-11-55 **Efficacy of apheresis for multiple organ failure**
Hida, M. (Japan)
- P-11-56 **Blood purification in patients with septic multi-organ failure**
Endoh, Y. (Japan)
- P-11-57 **Continuous hemofiltration and continuous hemodiafiltration in patients with septic multi-organ failure**
Endoh, Y. (Japan)
- P-11-58 **Clinical utility of endotoxin removal column in patients suffering from septic shock**
Ookawara, S. (Japan)
- P-11-59 **Effect of sequential application of two endotoxin absorption columns**
Morita, H. (Japan)

April 9 (Tue.)

April, 9 (Tue.)

Workshops

W-5 Donor apheresis: Recent advances and future development <i>Chairpersons: Shimizu, M. (Japan) & Matthes, G.A. (Germany)</i>	15:00-17:30 Room B1
--	--------------------------------------

- W-5-1 **Recent advances and future development of near donor processing of blood components**
Matthes, G.A. (Germany)
- W-5-2 **An automated plasma collection programme: A review of 30,000 procedures**
Woodfield, G.D. (New Zealand)
- W-5-3 **Leukocyte depletion and advantages of apheresed platelet concentrates**
Valbonesi, M. (Italy)
- W-5-4 **Automated plateletpheresis does not cause an increase in platelet activation in volunteer donors**
Ündar, L. (Turkey)
- W-5-5 **Patient/donor apheresis in gynecology and obstetrics**
Ueda, Y. (Japan)

W-6 Extracorporeal therapy for amyloidosis <i>Chairpersons: Gejyo, F. (Japan) & Jákó, J. (Hungary)</i>	15:00-17:30 Room B2
--	--------------------------------------

- W-6-1 **Clinical and pathological features of amyloidosis**
Jákó, J. M. (Hungary)
- W-6-2 **Amyloidosis: A new indication for extracorporeal elimination therapy?**
Weber, M. (Germany) & Borberg, H. (Germany)
- W-6-3 **Transthyretin-apheresis for the treatment of familial amyloidotic polyneuropathy: A pilot trial experience**
Costa, P.M.P. (Portugal)
- W-6-4 **Dialysis-related amyloidosis and clinical significance of extracorporeal removal of β 2-microglobulin**
Gejyo, F. (Japan)
- W-6-5 **Selective extracorporeal removal of β 2-microglobulin with adsorbent column in dialysis-related amyloidosis**
Nakazawa, R. (Japan)

April, 9 (Tue.)

W-7	Plasmapheresis for autoimmune skin diseases <i>Chairpersons: Takamori, K. (Japan) & Bystryrn, J.-C. (USA)</i>	15:00-17:30 Room C1
------------	---	------------------------

W-7-1 **Plasmapheresis for the treatment of pemphigus vulgaris**
Yamada, H. (Japan)

W-7-2 **The steroid-sparing effect of long-term plasmapheresis in pemphigus**
Søndergaard, K. (Denmark)

W-7-3 **Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies**
Bystryrn, J.-C. (USA)

W-7-4 **Immunoabsorption with tryptophan and phenylalanine columns as an effective treatment for pemphigus vulgaris**
Yaguchi, H. (Japan)

W-7-5 **Immunoabsorption for the treatment of bullous pemphigoid**
Ino, N. (Japan)

W-7-6 **Abolishing autoantibody production in pemphigus by synchronization of plasmapheresis and cyclophosphamide**
~~Euler, H.H. (Germany)~~ *Cancel*

W-7-7 **Apheresis therapy for pemphigus vulgaris with peptide antigen affinity column**
Hashimoto, K. (Japan)

W-8	Apheresis for the treatment of inflammatory bowel diseases <i>Chairpersons: Shimoyama, T. (Japan) & Axon, A.T. (UK)</i>	15:00-17:30 Room C2
------------	---	------------------------

W-8-1 **Leukocytapheresis with leukocyte removal filter for patients with inflammatory bowel disease**
Sawada, K. (Japan)

W-8-2 **Granulocytapheresis for inflammatory bowel disease**
Axon, A.T. (UK)

W-8-3 **Efficacy of centrifugal leukocytapheresis in active ulcerative colitis and study on its mechanism of the therapeutic effect**
Ayabe, T. (Japan)

W-8-4 **Treatment of Crohn's disease by lymphocyte apheresis: A randomized controlled trial**
Lerebours, E. (France)

W-8-5 **Cryofiltration for treatment of inflammatory bowel diseases**
Tamaki, T. (Japan)

April 9 (Tue.)

April, 10 (Wed.)

Plenary Lectures

PL-5	Apheresis available for transplantation Agishi, T. (Japan) <i>Chairperson: Klinkmann, H. (Germany)</i>	09:00-09:35 Room A
PL-6	The role of LDL apheresis in the treatment of familial hypercholesterolaemia Thompson, G.R. (UK) <i>Chairperson: Yamamoto, A. (Japan)</i>	09:35-10:10 Room A

Symposia

S-7	LDL and Lp(a) apheresis <i>Chairpersons: Kojima, S. (Japan) & Thompson, G.R. (UK)</i>	10:30-13:00 Room A
------------	---	-----------------------

- S-7-1 **Evaluation of LDL-apheresis: 15 years of experience in Cologne**
Borberg, H. (Germany)
- S-7-2 **Long-term safety and efficacy of LDL-apheresis using an automated dextran sulfate cellulose adsorption system**
Gordon, B.R. (USA)
- S-7-3 **Long-term effects of atherosclerosis in familial hypercholesterolemia treated by LDL-apheresis**
Koga, N. (Japan)
- S-7-4 **The LDL-apheresis atherosclerosis regression study**
Kroon, A.A. (The Netherlands)
- S-7-5 **The FHRS: A randomised comparison of therapeutic reduction of both LDL and Lp(a) versus LDL alone**
Kitano, Y. (Japan) & Thompson, G.R. (UK)
- S-7-6 **Lp(a)-apheresis: What we can say today**
Pokrovsky, S.N. (Russia)

S-8	Plasmapheresis in autoimmune neurologic diseases <i>Chairpersons: Sato, T. (Japan) & Cornblath, D.R. (USA)</i>	10:30-13:00 Room B1
------------	--	------------------------

- S-8-1 **Overview of plasma exchange in neuromuscular diseases**
Sato, T. (Japan) & Yoshino, H. (Japan)

April, 10 (Wed.)

- S-8-2 **Plasma exchange in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy**
Cornblath, D.R. (USA)
- S-8-3 **Plasma exchange in multiple sclerosis**
Noseworthy, J.H. (USA)
- S-8-4 **A newly designed column to treat autoimmune neurologic diseases by selective removal of CD4+T cells**
Matsuo, H. (Japan)
- S-8-5 **Plasma exchanges in rasmussen encephalitis**
Palcoux, J.-B. (France)
- S-8-6 **Plasmapheresis in treatment of adrenoleucodystrophy**
~~Bambauer, R. (Germany)~~ *Cancel*

S-9	Extracorporeal photochemotherapy update <i>Chairpersons: Laroche, L. (France) & Edelson, R.L. (USA)</i>	10:30-13:00 Room B2
------------	---	------------------------

- S-9-1 **Photopheresis: Clinical and mechanistic studies**
Edelson, R.L. (USA)
- S-9-2 **Alternative therapeutic modalities with extracorporeal photochemotherapy in Sezary syndrome**
Laroche, L. (France)
- S-9-3 **Extracorporeal photochemotherapy: A treatment for graft rejection**
~~Andreu, G. (France)~~ *Heshmati, F.*
- S-9-4 **Treatment and prevention of GvHD by ECP**
Sniecinski, I. (USA)
- S-9-5 **Update of extracorporeal photochemotherapy in autoimmune disorders**
Knobler, R.M. (Austria)

==== Oral Sessions ====

O-6	Rheology & photopheresis <i>Chairpersons: Schooneman, F. (France) & Fardji, A. (France)</i>	13:40-14:30 Room C1
------------	---	------------------------

- O-6-26 **Hemorheology and therapeutic haemapheresis an overview**
~~Schooneman, F. (France)~~ *Cancel*
- O-6-27 **The impact of plasmaexchange, selective adsorption and membrane differential separation on the blood rheologie**
Borberg, H. (Germany)

April, 10 (Wed.)

- O-6-28 **Photopheresis with oral psoralen and UV-A: Effects on haemostasis**
Faradji, A. (France)
- O-6-29 **Ultraviolet irradiation of blood**
Kalinin, N.N. (Russia)
- O-6-30 **Four years experience with extracorporeal photopheresis**
Schooneman, F. (France)

O-7 LDL and Lp(a) apheresis <i>Chairpersons : Amano, I. (Japan) & Schuff-Werner, P. (Germany)</i>	13:40-14:20 Room C2
--	------------------------

- O-7-31 **LDL-apheresis: Comparison between double-membrane filtration and dextran sulfate-cellulose adsorption**
Lalau, J.-D. (France)
- O-7-32 **A possible mechanism of hypotension occurred during LDL apheresis in patients taking ace inhibitors**
Kojima, S. (Japan)
- O-7-33 **Effects of LDL apheresis on renal injury in steroid-resistant focal segmental glomerulosclerosis**
Hattori, M. (Japan)
- O-7-34 **Comparison of Lp(a) and LDL rebound rates after LDL-apheresis procedures in 5 patients with familial hypercholesterolaemia**
Sussekov, A.V. (Russia)

Poster Sessions

P-12 Transplantation <i>Chairperson : Matsushita, M. (Japan)</i>	13:40-14:05 Room G
---	-----------------------

- P-12-60 **FK-506 elimination during continuous hemodiafiltration in a liver-transplanted patient**
Tsubo, T. (Japan)
- P-12-61 **Immunomodulation by cyclosporin A in pancreatic xenotransplantation in rabbits**
Gupta, R.C. (India)
- P-12-62 **Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood-type incompatible couples**
~~Tanabe, K. (Japan)~~ *Cancel*

April, 10 (Wed.)

- P-12-63 **Apheresis therapy on prolonged anemia after ABO-mismatched bone marrow transplantation**
Ohta, S. (Japan)
- P-12-64 **The effects of extracorporeal immunoabsorption combined with administration of anti-complement agents on hyperacute rejection of discordant hepatic xenografts**
Ota, K. (Japan)

P-13 Hepatic failure <i>Chairperson : Endo, Y. (Japan)</i>	14:05-14:30 Room G
---	-----------------------

- P-13-65 **Apheresis for fulminant hepatitis: Effects on clinical complications**
Kitamura, M. (Japan)
- P-13-66 **Serum α -fetoprotein level and the arterial ketone body ratio in patients with acute hepatic failure**
Saibara, T. (Japan)
- P-13-67 **Collaborative factors in the treatment of hepatic failure by blood purification**
Endo, Y. (Japan)
- P-13-68 **Plasma exchange and serum concentration of organic acids in patients with acute hepatic failure**
Saibara, T. (Japan)
- P-13-69 **Hybrid artificial liver using hepatocytes entrapped with collagen gel in a hollow fiber device**
Yamamoto, T. (Japan)

P-14 Training and practice in apheresis (I) <i>Chairperson : Yonekawa, M. (Japan)</i>	13:40-14:10 Room H
--	-----------------------

- P-14-70 **Increase of peripheral blood leukocytes and chemokines during immunoabsorbent therapy**
Ota, K. (Japan)
- P-14-71 **Transient decrease of peak expiratory flow rate during immunoabsorbent therapy**
Ikusaka, M. (Japan)
- P-14-72 **Orthopedic and vocational rehabilitation by plasmapheresis in rheumatoid arthritis**
Srivastava, R. (India)

April 10 (Wed.)

April, 10 (Wed.)

- P-14-73 **Therapeutic apheresis training program in India**
Srivastava, R. (India)
- P-14-74 **Evaluation of biocompatibility of polymyxin B immobilized fiber both in fundamental and clinical study**
Hanasawa, K. (Japan)
- P-14-75 **Influence of continuous hemodialysis and filtration on the patient and on the kinetics of granulocyte elastase, cytokines and medium-molecular substances**
Akahori, M. (Japan)

P-15 **Training and practice in apheresis (II)**

Chairperson : Yokoyama, H. (Japan)

14:10-14:35

Room H

- P-15-76 **Fibrinogen-lowering by apheresis: Efficiency of different methods and possible clinical implication**
Schuff-Werner, P. (Germany)
- P-15-77 **Does apheresis provide better quality FFP and cryoprecipitate?**
Seghatchian, M.J. (UK)
- P-15-78 **Storage induced changes in cellular integrity of apheresis and buffy coat derived platelets**
Seghatchian, M.J. (UK)
- P-15-79 **Removal of plasminogen activator inhibitor-1 from plasma by plasmapheresis associated with improvement of HELLP syndrome: A new trial of hemofiltration using EVAL 2A filter**
Eguchi, Y. (Japan)
- P-15-80 **Use of cell separators in therapeutic plasma exchange in India: An economic solution**
Srivastava, R. (India)

P-16 **System development in practice**

Chairperson : Endoh, Y. (Japan)

14:35-14:55

Room H

- P-16-81 **The experience of the use of plasma exchange in an area hospital**
Kao, M.-T. (Taiwan)
- P-16-82 **Role of blood center on peripheral blood stem cell transplantation**
Sato, N. (Japan)
- P-16-83 **New definitions of French blood components**
~~Schooneman, F. (France)~~ *Claise, C.*

April, 10 (Wed.)

P-16-84 **Plasma exchanges in medical practice for ICU**
Schwebel, C. (France)

Workshops

W-9 Development and evaluation of new apheresis techniques in the treatment of atherosclerosis and some related diseases <i>Chairpersons: Koga, N. (Japan) & Pokrovsky, S. N. (Russia)</i>	15:00-17:30 Room B1
---	------------------------

W-9-1 **Lipoprotein (a) apheresis, blood cells and status of CAD patients**
Schmitz, G. (Germany)

W-9-2 **Lipoprotein(a), endothelium dysfunction and possibility for extracorporeal correction**
Sussekov, A.V. (Russia)

W-9-3 **Dextran-sulfate as an adsorbent of several proteins other than LDL**
Kojima, S. (Japan)

W-9-4 **Selective removal of plasma component by high-performance immunoaffinity chromatography**
Kojima, K. (Japan)

W-9-5 **An important role of oxidative LDL in progression of hyperlipidemic disease evidenced from LDL apheresis**
Sanaka, T. (Japan)

W-9-6 **The H.E.L.P. system: Clinical experience of 10 years - A report**
~~Seidel, D. (Germany)~~ *Schuff - Werner*

W-9-7 **Single LDL-apheresis improves endothelium-dependent vasodilation**
Imaizumi, T. (Japan)

W-10 Therapeutic cytapheresis <i>Chairpersons: Kawamura, A. (Japan) & Woodfield, D.G. (New Zealand)</i>	15:00-17:30 Room B2
--	------------------------

W-10-1 **Therapeutic cytapheresis and haemopoietic stem cell collection**
Isbister, J.P. (Australia)

W-10-2 **Granulocytapheresis in patients with advanced cancer and rheumatoid arthritis**
Yonekawa, M. (Japan)

W-10-3 **Leukocytapheresis for patients with primary biliary cirrhosis and autoimmune hepatitis**
Sawada, K. (Japan)

April 10 (Wed.)

April, 10 (Wed.)

- W-10-4 **Lymphocyteapheresis for patients with RA using polyester filter compare with double-filtration plasmapheresis**
Kanai, Y. (Japan)
- W-10-5 **Advantages of isovolemic large volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for RBC depletion in patients with polycythemia vera (primary erythrocytosis)**
Kaboth, U. (Germany)
- W-10-6 **Treatment of idiopathic haemochromatosis by using erythroapheresis in combination with repeated venesections**
Saibara, T. (Japan)

W-11 Use of filtration technology for reducing the infectivity of blood components
Chairpersons: Sekiguchi, S. (Japan) & Friedman, L.I. (USA)

15:00-17:30
Room C1

- W-11-1 **Virus inactivation / removal in blood components**
Friedman, L.I. (USA)
- W-11-2 **Use of leukoreduction filtration to remove CMV from blood components**
Slichter, S.J. (USA)
- W-11-3 **Studies on the effectiveness of leukoreduction filtration in removing HTLV and HIV from blood components**
Takahashi, T.A. (Japan)
- W-11-4 **Use of filters to remove viruses from plasma derivatives**
Satoh, S. (Japan)
- W-11-5 **Filter application to remove viruses from fresh frozen plasma**
Ikeda, H. (Japan)

W-12 New devices
Chairpersons: Sakai, S. (Japan) & Sueoka, A. (USA)

15:00-17:30
Room C2

- W-12-1 **Recent progress of immunoadsorption**
Takenaka, Y. (Japan)
- W-12-2 **Newly developed IgG adsorbent CF-X**
Matsuda, Y. (Japan)
- W-12-3 **Immunoglobulinadsorption in SLE: Experiences with 10 patients**
Gaubitz, M. (Germany)

April, 10 (Wed.)

- W-12-4 Efficacy of an extracorporeal granulotrap column, G-1 in rheumatoid arthritis disease**
Saniabadi, A.R. (Japan)
- W-12-5 Strategy of leukocyte filtration for immunomodulation: Development of stainless steel leukocyte filter**
Yamaji, K. (USA)
- W-12-6 Application of pulsed magnetic fields for cellular immunomodulations**
Murabayashi, S. (Japan)

April 10 (Wed.)

SOCIAL PROGRAM

Opening Ceremony

Sunday, April 7, 17:30 - 19:00 in Room A

Special Lecture

Sunday, April 7, 18:00 - 18:30 in Room A

Chairperson: Akira Yamamoto
(National Cardiovascular Center Research Institute)

“Apheresis Techniques as a New Direction of Artificial Organ Development”

Tetsuzo Agishi (Kidney Center, Tokyo Women’s Medical College)

*There will be simultaneous interpretation through Opening Ceremony and Special Lecture.

Welcome Reception

Sunday, April 7, 19:00 - 20:30 in the Swan Room

Mixer

Monday, April 8, 17:30 - 19:30 in Room D

A video entitled “**Social and Cultural Factors and the Prevention of Atherosclerosis in Japan**” and a lecture entitled “**Some Aspects of Japanese Textile**” by Prof. Yasuko Betchaku (Visiting Professor, International Research Center for Japanese Studies) will be presented.

A complimentary meal will be served in the Swan Room. A limited number of free tickets will be available at the general information desk. Reservations will be accepted on a first-come, first-served basis.

Banquet

Tuesday, April 9, 18:00 -20:00 in the Sakura Room

Fee ¥6,000

General Assembly

Tuesday, April 9, 13:00 - 14:00 in Room A

Program for Accompanying Persons

Ikebana flower arranging

Monday, April 8, 14:00 - 16:00 in Room 501

Fee ¥3,000

Dress at all the above social events is informal.

REGISTRATION

Registration: Fees, Payment, and Site

Active members	¥40,000
Residents, Students and Co-medical	¥15,000
Accompanying persons	No charge
Banquet	¥6,000

All payments must be made in **Japanese yen** with cash or a credit card. MasterCard, VISA, American Express, and Diners Club are accepted.

Only on-site registration is available. The registration desk will open from Sunday, April 7, at the main lobby of the Kyoto International Conference Hall according to the following schedule:

Sunday, April 7	08:30 - 19:00
Monday, April 8	08:00 - 17:00
Tuesday, April 9	08:00 - 17:00
Wednesday, April 10	08:00 - 12:00

*To register as a resident, you must be under 30 years of age and must submit a letter of certification issued by the appropriate department head or program director. Students must present a student ID.

Registration Entitlements

Conference delegates and registered residents are entitled to

- attend the Opening Ceremony
- participate in all scientific sessions
- attend the Welcome Reception
- receive a set of official publications.

Accompanying persons are entitled to

- attend the Opening Ceremony
- attend the Welcome Reception.

Cancellation Policy

All cancellations must be in writing and addressed to the secretariat. Requests for cancellation received by February 28, 1996, will be subject to an administrative charge of ¥3,000. No refunds will be made for cancellations received after that date. All refunds will be made after the conference.

GENERAL INFORMATION

Airport Tax

All air travelers leaving Japan from New Tokyo International Airport (Narita Airport) will be required to pay a facility user fee of ¥2,000, payable only in Japanese yen. Those leaving through Kansai International Airport must pay a facility user fee of ¥2,600.

Banks

Business hours: Monday to Friday, 09:00 -15:00
Closed on Saturdays, Sundays and public holidays
All banks offer the same exchange rate.

Climate and Clothing

The climate in Kyoto in April ranges between 9°C (48°F) at night and 20°C (68°F) during the day. The weather, however, is often unpredictable during this season. The average humidity is 63%, so light clothing and a sweater or light coat are recommended. Hotels and the conference hall are fully air conditioned.

Cloak Room

Cloak rooms are situated near the main entrance and next to the grill.

Consumption Tax

A national consumption tax of 3% will be added to the cost of almost all commodities and services you purchase in Japan.

Currency

Most foreign currencies and traveler's checks are easily exchanged at banks and hotels. A passport may be required for currency-exchange services.

The exchange rate as of January 1996 was approximately US\$1 = ¥106 - 7. The secretariat will accept only yen in cash.

Daily Expenditures in Kyoto

Although this depends on one's lifestyle and budget, most visitors to Kyoto find that ¥5,000 per day covers meals, public transportation, etc., excluding hotel charges.

Electricity

Electricity is supplied as 100 volts alternating current at a frequency of 60 Hz.

Health Documents

Health documents are not required for visitors from most western countries, but requirements vary from country to country. Travelers arriving from areas where cholera or yellow fever is endemic require vaccination certificates.

Insurance

The organizing committee can accept no responsibility for accidents or damage to the private property of participants. Please make your own arrangements for health insurance and any other insurance desired.

Kyoto

The ancient capital of Japan, Kyoto is nestled among picturesque mountains and placid rivers. Since its establishment as the seat of the imperial court late in the 8th century, the city has prospered as a center of politics, commerce, culture, and the arts. With its innumerable cultural treasures and traditional crafts, Kyoto has continued to attract visitors from around Japan and throughout the world. Today it is a modern metropolis with an international flavor; indeed, perhaps nowhere else in Japan can one so easily encounter the past in the midst of an urban culture eagerly preparing for the 21st century.

Lunch

Visitors may also purchase lunches at the snack bar on the fourth floor and the grill on the first floor of KICH. The Sakura Banquet Hall also offers a varied menu. There are also several snack bars and restaurants in the neighborhood. Please refer to the Lunch Map.

Postal Services and Telephone Services

Many hotels provide basic postage services. Post offices are open daily except Saturdays, Sundays and public holidays. You can mail letters at post offices or use the red public mailboxes. Public telephones are available everywhere, but only those marked as such can accept international calls. Pay telephones are available in KICH. Pay telephones accept Japanese coins and prepaid telephone cards.

Public Transport

For general transport, taxis are plentiful and relatively inexpensive. In addition, subways provide easy access to Kyoto Station. Public buses operate frequently.

Refreshments

Refreshments will be served (with coupons or cash) during breaks. Coupons will be distributed with registration materials at the registration desk.

Restaurants

Kyoto is known for its refined cuisine. There are many restaurants specializing in Japanese dishes as well as Eastern and Western cuisine.

Shopping

Most shops and department stores are open Sundays and holidays until early evening; however, they normally close on one weekday, usually Wednesdays. Street markets are open every day until 8:00 p.m.. Kyoto is a shoppers' delight for antiques, pottery, and crafts. Major credit cards are accepted.

Shuttle Bus

A shuttle bus will run between Kitayama Subway Station (Exit No. 3) and KICH, and between the Kyoto Holiday Inn and KICH in the mornings and evenings of the conference.

Kitayama Subway Station to KICH		KICH to Kitayama Subway Station
April 7	08:30 - 17:45, every 15 minutes beginning on the hour	20:00 - 21:30, every 15 minutes
April 8	08:00 - 09:00, every 5 - 15 minutes	17:30 - 18:30, every 15 minutes 19:30 - 20:30, every 15 minutes
April 9	08:00 - 09:00, every 5 - 15 minutes	17:30 - 18:30, every 15 minutes 20:00 - 21:00, every 15 minutes
April 10	08:00 - 09:00, every 5 - 15 minutes	17:00 - 18:00, every 15 minutes

Kyoto Holiday Inn to KICH		KICH to Kyoto Holiday Inn
April 7	16:30, 16:45	20:30
April 8	08:00, 08:20, 08:40	19:30
April 9	08:00, 08:20, 08:40	20:00
April 10	08:00, 08:20, 08:40	17:30

Time

Japan time is 9 hours ahead of Greenwich Mean Time.

Tipping


Tipping is not customary in Japan. Tips are usually included in the bill as a service charge.

EXHIBITION

Exhibitors' List


Exhibitors	Booth No.	Exhibitors	Booth No.
Amco Incorporated	4	Medical Soft Support Center Corp.	19
Asahi Medical Co., Ltd.	14	Medikit Co., Ltd.	9
Baxter Limited	5	Nikkiso Co., Ltd.	8
Chugai Pharmaceutical Co., Ltd.	17	Nipro Co., Ltd.	12
Cobe Laboratories, K.K.	18	Otsuka Pharmaceutical Factory, Inc.	2
Fukuda Denshi	11	Sankyo Co., Ltd.	3
Haemonetics Japan	15	Terumo Corporation	13
Kaneka Corporation	10	Toray Medical Co., Ltd.	6
Kuraray Co., Ltd.	16	Ube Medical Co., Ltd.	1
		Vilber Lourmat & Yayoi Co., Ltd.	7

ROOM E



MEMO

MAP



- ① Takaragaike Prince Hotel
- ③ Karasuma Kyoto Hotel
- ⑤ Hotel Gimmond
- ⑦ Maruko Inn Kyoto

- ② Holiday Inn Kyoto
- ④ Hotel Keihan Kyoto
- ⑥ Kyoto Garden Hotel